ReviewMediators of inflammation2015
Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Qoppa as a New Pan-Tumor Synthetic Parameter Derived from Tumor-Associated Biomarkers for Identifying Oncology Patients at High Risk of Metastasis: A Prospective Pilot Study.Journal of clinical medicine · 2026Article
- The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy.Biomedicines · 2025Review
- Impact of body composition and muscle health phenotypes on survival outcomes in colorectal cancer: a multicenter cohort.Scientific reports · 2024Article
- Adipokines and epithelial-mesenchymal transition (EMT) in cancer.Molecular and cellular biochemistry · 2023Review
- Cytarabine induces cachexia with lipid malabsorption via zippering the junctions of lacteal in murine small intestine.Journal of lipid research · 2023Article
- High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Review
- Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer during chemotherapy: a case-control study.Medical oncology (Northwood, London, England) · 2022Article
- Article
- Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene.Frontiers in cell and developmental biology · 2022Review
- Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia.The Journal of experimental medicine · 2021Article
- Article
- Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison.Pharmacological reports : PR · 2021Review
- The Adipokines in Cancer Cachexia.International journal of molecular sciences · 2020Review
- Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.Biochimica et biophysica acta. Reviews on cancer · 2020Review
- Plasma Metabolomics Identifies Lipid and Amino Acid Markers of Weight Loss in Patients with Upper Gastrointestinal Cancer.Cancers · 2019Article
- MyD88 signalling is critical in the development of pancreatic cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2019Article
- Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives.Frontiers in oncology · 2019Article
- Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study.Journal of cachexia, sarcopenia and muscle · 2018Article
- Metformin Mitigates Fibrosis and Glucose Intolerance Induced by Doxorubicin in Subcutaneous Adipose Tissue.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fat loss is associated with shorter survival and reduced quality of life in cancer patients. Effective intervention for fat loss in cachexia requires identification of the condition using prognostic biomarkers for early detection and prevention of further depletion. No biomarkers of fat mass alterations have been defined for application to the neoplastic state. Several inflammatory cytokines have been implicated in mediating fat loss associated with cachexia; however, plasma levels may not relate to adipose atrophy. Zinc-α2-glycoprotein may be a local catabolic mediator within adipose tissue rather than serving as a plasma biomarker of fat loss. Plasma glycerol and leptin associate with adipose tissue atrophy and mass, respectively; however, no study has evaluated their potential as a prognostic biomarker of cachexia-associated fat loss. This review confirms the need for further studies to identify valid prognostic biomarkers to identify loss of fat based on changes in plasma levels of biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.